Through the newly signed deal, Healthtrust will gain access to TriReme’s portfolio of specialty angioplasty balloons designed to treat blood vessel blockage due to arterial disease, QT Vascular said.
Nashville, Tenn.-based HealthTrust serves more than 1,400 acute care facilities and members at more than 22,600 locations which include ambulatory surgery centers, phsyician practices, long-term care and alternate care sites, the company said.
QT Vascular said that the agreement is not expected to have a material effect on losses per share for the end of the upcoming financial year, according to a press release.
Last week, QT Vascular said it won full FDA investigational device exemption approval to initiate a trial of its Chocolate Touch drug-coated balloon designed to treat vascular disease.
The Singapore-based company said it looks to enroll 585 patients at up to 50 US centers for the prospective, randomized trial, which aims to explore the use of the device for treating patients with vascular disease in the superficial femoral and popliteral arteries in the legs.
The Chocolate Touch will be compared against Bard’s Lutonix drug-coated balloon, with acute study endpoints evaluating procedural success, freedom from bail-out stenting and long-term endpoints such as patency and target lesion revascularization, QT Vascular said.